Modern approaches to the pharmacotherapy of postpartum depression

Postpartum or postnatal depression (PDD) is a common disorder that has serious negative effects on a woman’s health and increases the risk for a child’s emotional, social, and cognitive development outcomes. There are a few unresolved problems in the PDD pharmacotherapy caused by the lack of evidenc...

Full description

Bibliographic Details
Main Authors: A. V. Ovchinnikov, T. I. Vazagaeva
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-08-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/5755
_version_ 1797841980254846976
author A. V. Ovchinnikov
T. I. Vazagaeva
author_facet A. V. Ovchinnikov
T. I. Vazagaeva
author_sort A. V. Ovchinnikov
collection DOAJ
description Postpartum or postnatal depression (PDD) is a common disorder that has serious negative effects on a woman’s health and increases the risk for a child’s emotional, social, and cognitive development outcomes. There are a few unresolved problems in the PDD pharmacotherapy caused by the lack of evidence about drug safety and effectiveness. This review provides a timely update on the current understanding of approaches to the diagnosis and treatment of patients with PDD as part of recurrent depression and bipolar disorder, the features of pharmacotherapy in the postpartum period depending on the manifestations and course of the disease. In accordance with the current guidelines, the treatment of PDD requires the use of the same standard approaches, as in the treatment of depression not associated with pregnancy and childbirth, while it is recommended to refuse breastfeeding in most cases, which runs somewhat contrary to the literature. Several clinical studies have shown that some psychotropic drugs are safe to use in breastfeeding mothers as they demonstrate low transfer into breast milk and rarely cause adverse events in infants. With this respect, sertraline is regarded as the first choice among antidepressants (AD), and quetiapine and valproate among normotimics, however, the limited amount of data does not allow us to make final conclusions about short-term and long-term risks for children. The article also outlines promising directions in the development of new neurosteroid-based antidepressant drugs for the treatment of PDD. Their mechanism of action is mainly associated with a modulating effect on GABAergic neurotransmission.
first_indexed 2024-04-09T16:40:20Z
format Article
id doaj.art-8b61a61b39fb4be5a39599874bbfa2ba
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:40:20Z
publishDate 2020-08-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-8b61a61b39fb4be5a39599874bbfa2ba2023-04-23T06:56:44ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902020-08-01011708110.21518/2079-701X-2020-11-70-815235Modern approaches to the pharmacotherapy of postpartum depressionA. V. Ovchinnikov0T. I. Vazagaeva1V.P. Serbsky National Medical Research Centre for Psychiatry and NarcologyV.P. Serbsky National Medical Research Centre for Psychiatry and NarcologyPostpartum or postnatal depression (PDD) is a common disorder that has serious negative effects on a woman’s health and increases the risk for a child’s emotional, social, and cognitive development outcomes. There are a few unresolved problems in the PDD pharmacotherapy caused by the lack of evidence about drug safety and effectiveness. This review provides a timely update on the current understanding of approaches to the diagnosis and treatment of patients with PDD as part of recurrent depression and bipolar disorder, the features of pharmacotherapy in the postpartum period depending on the manifestations and course of the disease. In accordance with the current guidelines, the treatment of PDD requires the use of the same standard approaches, as in the treatment of depression not associated with pregnancy and childbirth, while it is recommended to refuse breastfeeding in most cases, which runs somewhat contrary to the literature. Several clinical studies have shown that some psychotropic drugs are safe to use in breastfeeding mothers as they demonstrate low transfer into breast milk and rarely cause adverse events in infants. With this respect, sertraline is regarded as the first choice among antidepressants (AD), and quetiapine and valproate among normotimics, however, the limited amount of data does not allow us to make final conclusions about short-term and long-term risks for children. The article also outlines promising directions in the development of new neurosteroid-based antidepressant drugs for the treatment of PDD. Their mechanism of action is mainly associated with a modulating effect on GABAergic neurotransmission.https://www.med-sovet.pro/jour/article/view/5755postpartum depressiondepressionpharmacotherapyantidepressantslactationneurosteroids
spellingShingle A. V. Ovchinnikov
T. I. Vazagaeva
Modern approaches to the pharmacotherapy of postpartum depression
Медицинский совет
postpartum depression
depression
pharmacotherapy
antidepressants
lactation
neurosteroids
title Modern approaches to the pharmacotherapy of postpartum depression
title_full Modern approaches to the pharmacotherapy of postpartum depression
title_fullStr Modern approaches to the pharmacotherapy of postpartum depression
title_full_unstemmed Modern approaches to the pharmacotherapy of postpartum depression
title_short Modern approaches to the pharmacotherapy of postpartum depression
title_sort modern approaches to the pharmacotherapy of postpartum depression
topic postpartum depression
depression
pharmacotherapy
antidepressants
lactation
neurosteroids
url https://www.med-sovet.pro/jour/article/view/5755
work_keys_str_mv AT avovchinnikov modernapproachestothepharmacotherapyofpostpartumdepression
AT tivazagaeva modernapproachestothepharmacotherapyofpostpartumdepression